Pressures on healthcare will see European companies forced into foreign ownership
This article was originally published in Clinica
The inevitable drive for efficiency will leave Europe without a substantial medtech industry of its own. Cross-border mergers may be fraught with difficulties, according to Donald Meltzer of Credit Suisse First Boston, but, with the increasing emphasis on cost efficiency, further developments in this area are inevitable.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.